Alector, Inc. Stock News

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for ​Parkinson's disease, the US biotech said ‌on Monday, sending its shares surging 72% in premarket trading.

Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, Septe...

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's dis...

Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering ​two experimental antibody drugs after both ‌the drug candidates suffered clinical setbacks.

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint –  --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for mult...